Alnylam Reports Increased Q4, 2005
Losses Amid Higher R&D Spending

Alnylam Pharmaceuticals this week reported its financial results for the fourth quarter and full-year 2005, posting widening losses amid increased research and development spending.

For the fourth quarter, Alnylam's net loss rose to $14.5 million, or $0.56 per share, from $5.7 million, or $0.29 per share, in the year-ago quarter. For 2005, the company's net loss jumped to $42.9 million, or $1.96 per share, from $35.4 million, or $2.98 per share, the year before.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.